ZYDUSLIFEZydus Lifesciences Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market Cap₹91,104 Cr
Primary DriverEarnings Quality
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
7 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in profitability and earnings quality. This indicates that forensic pressure is currently receding. Risk levels are improving.

17.2th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹1,078.3▼1.18%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Earnings Quality
+6.0 pts
Stability Adjustment
+1.0 pts
Final Composite Risk7 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 5 → 7 over 13 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Industrial Margin Stress
  • Operating Leverage Stress
What to Watch Next Quarter
  • Operating profit margins
  • Operating cash flow
  • Debt growth

Active Risk Objects (4)

CriticalHigh
Industrial Margin Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ3 FY2026
ZYDUSLIFE: EBITDA margin compressed by 6.5 bps YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Cash Conversion Deficit
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight6/15
MomentumAccelerating
Last SignalFY2026
ZYDUSLIFE: OCF below Net Profit in 2/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Operating Leverage Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ4 FY2026
Expenses are consistently growing faster than revenues, creating operational pressure.

"Debt levels are creeping up. Monitor for signs of excessive borrowing for non-core activities."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ2 FY2026
Inventory growth (27.8%) significantly outpaced revenue growth (17.5%).

"Slight build-up in inventory detected. Monitor for slowing sales momentum."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)1.837.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+59.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,078.3(-1.18%)
1M Divergence+18.63%
1 Week-0.07%
1 Month+20.9%
6 Months+15.23%
1 Year+17.53%
2 Year+9.32%
3 Year+113.04%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in earnings quality remain well-maintained against forensic benchmarks. Systematic scans of operational margins and profitability metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

ZYDUSLIFE • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.85%
Trend QualityDeveloping
Phase Progression
Phase Progression Score75%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing85%
CoinTree Momentum
Composite Z-Score+0.5746σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#410 of 2716
Top 15.10% in momentum strength
Timeframe Sparklines
1W-0.1%
1M+20.9%
6M+15.2%
Weinstein Indicators
150 DMA₹929.23
200 DMA₹947.22
150 DMA Slope+0.1882%Rising
Relative Strength+20.72%Leading
Relative Turnover (RTR)2.0628
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).
ABBOTINDIAABBOTINDIA
0 Risk
Sector %ile0th
Delta0
Active Flags0
Accel+0
Governance

Stable

ZYDUSLIFEZydus Lifesciences Limited
7 Risk
Sector %ile17th
Delta-5
Active Flags4
Accel+0
Earnings Quality

Stable

AARTIDRUGSAarti Drugs Limited
19 Risk
Sector %ile51th
Delta-5
Active Flags11
Accel+0
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
660th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Operating Leverage Stress

2026

Industrial Margin Stress

2026

Industrial Margin Stress

2026

Inventory Stress

2026

Operating Leverage Stress

2026

Cash Conversion Deficit

2024

Cash Conversion Deficit

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY202627,6585,1242,11711,770
FY202523,5114,6736,7773,170
FY202419,8323,9733,228769
FY202317,4242,0922,6891,163